Name: setting-up an in vitro model of rat blood-brain barrier (bbb): a focus on bbb impermeability and receptor-mediated transport
Uploaded: 2014-06-28T14:00:00
Duration: 16 min 26 s
Description: Watch this Scientific Journal Video about Setting-up an In Vitro Model of Rat Blood-brain Barrier BBB: A Focus on BBB Impermeability and Receptor-mediated Transport at JoVE.com

Financial support to VECT-HORUS is acknowledged from the Fonds Unique Interminist&#233;riel (FUI/ MEDUL project) and to VECT-HORUS and the UMR7259 laboratory from the Agence Nationale de la Recherche (ANR, TIMPAD, VECtoBrain, VEC2Brain, ADHOC and PREVENTAD collaborative projects). The UMR7259 laboratory also acknowledges financial support from the CNRS and from Aix-Marseille Universit&#233;.

1. Production of Rat Astrocytes
For each preparation use 10 neonatal Wistar rats of either sex.
<ol>
	<li>Sacrifice the rats by cutting heads with a pair of scissors and transfer them immediately in a dry Petri dish under a laminar flow hood. Remove the brains from the skull without the cerebellum and transfer them immediately into a Petri dish containing cold dissection buffer: HBSS supplemented with 1% Bovine Serum Albumin&#160;(low level of endotoxin BSA), penicillin 100 units/ml&#160;and streptomycin 100 &#181;g/ml.</li>
	<li>Cut the brains in half, to separate the 2 cerebral hemispheres and transfer them into a clean Petri Dish with dissection buffer on ice. Cut the optic nerve and remove the meninges under a stereomicroscope.</li>
	<li>Wash the cortical pieces extensively in 50 ml of cold dissection buffer.</li>
	<li>Place the cortical pieces from 3 brains into a 15 ml Falcon tube and dissociate by pipetting up and down a couple of times with a 10 ml disposable pipette equipped with a blue tip into 6 ml of trypsin 0.05% - EDTA 0.02% for 5 min at 37 &#176;C.</li>
	<li>Add 24 ml of DMEM supplemented with 10% FBS and the following antibiotics, penicillin 100 units/ml and streptomycin 100 &#181;g/ml, a media named glial cell media (GCM), and centrifuge at 300 x g for 5 min at RT. FBS batches were selected and validated for the growth and survival of astrocyte cutures.</li>
	<li>Resuspend the pellet containing the dissociated cells in 10 ml GCM and plate into a 75 cm2 T-flask (T75). Change the medium the following day to remove the cell debris and DNA. Replace the culture media twice a week.</li>
	<li>After 1 week of proliferation, gently shake the glial cells with an orbital shaker at 60 rpm during 24 hr at 37 &#176;C in GCM. If the T75 cannot be placed in an incubator with 5% CO2 / 95% air at 37 &#176;C humidified atmosphere, supplement the media with 5 mM HEPES. Wash the cells twice to remove the non-adherent microglial cells.</li>
	<li>Three weeks after seeding, wash the cells twice with DPBS without calcium and magnesium. Add 3 ml of warm trypsin 0.05%-EDTA 0.02%, incubate at 37 &#176;C and wait until the cell layer is dispersed (usually 5 min). Inhibit trypsin activity by adding 10 ml of GCM, transfer the cell suspension into a 15 ml Falcon tube and centrifuge at 120 x g for 8 min.</li>
	<li>Resuspend the astrocyte pellet in 90% FBS &#8211; 10% DMSO, transfer them into cryovials (2 x 106 cells per cryovial) and store in liquid nitrogen.</li>
</ol>
2. Isolation of Rat Brain Microvessels
Our experimental procedures are approved by the Ethics Committee of the Medical Faculty of Marseille and conform to National and European regulations (EU directive No. 86/609). All efforts were made to minimize animal suffering and reduce the number of animals used.
<ol>
	<li>For each preparation and for one experimenter, use 3 five week old Wistar rats.</li>
	<li>Monday of the first week, prepare 2 T75 flasks by coating with collagen type IV and fibronectin, both at 1 &#181;g/cm2 in sterile culture water (10 ml per T75). Allow to adhere at 37 &#176;C until microvessel seeding.</li>
	<li>Wednesday morning of the first week, euthanize the rats under an increasing flux of CO2 to induce drowsiness, loss of posture and breathing interruption, then followed by a cervical dislocation. Spray the heads with 70% ethanol. Cut the heads with a pair of scissors and transfer them into a dry Petri dish under a laminar flow hood.</li>
	<li>Remove the brains from the skull without the cerebellum and the optic nerves, then transfer them into a Petri dish cooled on ice and filled with cold dissection buffer (HBSS supplemented with 1% BSA, penicillin 100 units/ml and streptomycin 100 &#181;g/ml).</li>
	<li>Cut the brains in half to separate the 2 cerebral hemispheres and separate midbrain from forebrain. Transfer the forebrains into a clean Petri dish on ice with dissection buffer.</li>
	<li>Take a couple of hemispheres in a new Petri dish with cold dissection buffer to carefully remove the meninges from the forebrains under a stereomicroscope with N&#176; 5 curved forceps. Then, clean the interior of the brain to remove the duvet of myelin and obtain a shell of cortex. These steps should not take more than 2 hr for tissue preservation and cell survival.</li>
	<li>Dissociate the cortex from 3 brains into 6 ml of cold dissection buffer in a 7 ml dounce homogenizer by 10 up and down strokes with each of 2 pestles of different clearances, 71 &#181;m followed by 20 &#181;m.</li>
	<li>Divide the suspension to obtain the equivalent of 1 cortex in 1 ml of a 50 ml Falcon tube and centrifuge at 1,000 x g for 5 min at RT. Discard the supernatant.</li>
	<li>Digest the suspension from 1 cortex with 1 ml of an enzymatic solution containing a mix of collagenases / dispase (60 &#181;g/ml &#8211; 0.3 U/ml), DNase type I (35 &#181;g/ml &#8211; 20 K units/ml) and gentamicin (50 &#181;g/ml) in a shaker for 30 min at 37 &#176;C.</li>
	<li>Mix the 1 ml digest from 1 cortex with 10 ml of 25 % BSA/HBSS 1X and separate by density dependent centrifugation at 3,600 x g for 15 min at RT. Carefully transfer the upper disk (myelin and brain parenchyma) and the supernatant into a clean 50 ml Falcon tube and repeat the centrifugation. Keep the resulting pellet containing the brain microvessels at 4 &#176;C.</li>
	<li>Carefully discard the upper disk and the supernatant. Resuspend both resulting pellets containing the brain microvessels with 1 ml of cold HBSS 1X and transfer into a clean 50 ml Falcon tube.</li>
	<li>Wash the microvessels by addition of 20 ml of cold HBSS 1X and centrifuge at 1,000 x g for 5 min. Discard the supernatant.</li>
	<li>Further digest the microvessels from 1 cortex with 1 ml of the same enzymatic solution as described in step 2.9 during 1 hr at 37 &#176;C in a shaker.</li>
	<li>Then, mix the digested microvessels from each of the 3 cortices into one tube and further separate into two 50 ml Falcon tubes to obtain microvessels extracted from the equivalent of one and a half (1.5) cortex per tube. Add 30 ml of cold dissection buffer and centrifuge at 1,000 x g for 5 min at RT.</li>
	<li>Resuspend the microvessel pellet in 10 ml of DMEM/F12 supplemented with 20% bovine platelet poor plasma derived serum, basic fibroblast growth factor (bFGF, 2 ng/ml), heparin (100 &#181;g/ml), gentamicin (50 &#181;g/ml) and HEPES (2.5 mM), named endothelial cell media (ECM) supplemented with puromycin at 4 &#181;g/ml.</li>
	<li>Take the 2 coated T75 flasks from the incubator, aspirate the excess of coating and plate the microvessels from each tube in one T75 flask (microvessels extracted from 1.5 cortex per T75 flask).</li>
</ol>
3. Purification and Proliferation of RBEC Primocultures
<ol>
	<li>Purification: Wednesday to Friday, add puromycin at 4 &#181;g/ml to the culture media. Change the medium on Thursday. On Friday, wash the cells and add puromycin at 2 &#181;g/ml until Monday.</li>
	<li>Proliferation: on Monday of the second week, wash the cells and add insulin, transferrin and sodium selenite supplement to the culture media until the cultures reach 90% confluence on Wednesday of the second week.</li>
</ol>
4. Differentiation: Setting up the In Vitro BBB Model
<ol>
	<li>Monday of the second week, prepare filters (polyethylene, 12 wells, pore size 1.0 &#956;m) by coating with a mix of collagen type IV and fibronectin both at 0.5&#181;g/cm2 in sterile culture water (500 &#181;l of mix in the upper compartment and 1.5 ml of sterile culture water in the lower compartment). Allow to adhere at 37 &#176;C until RBEC seeding.</li>
	<li>Monday of the second week, five days before the establishment of the co-culture, thaw the astrocytes from cryovials at 37 &#176;C and transfer in a 15 ml Falcon with 10 ml GCM. Centrifuge the suspension at 120 x g for 8 min at RT.</li>
	<li>Resuspend the astrocyte pellet in GCM and plate at a density of 30 x 103 cells per cm2 in 12-well plates.</li>
	<li>Wednesday of the second week, just before dissociation of RBEC with trypsin, wash twice the pre-coated filter with DMEM/F12 medium. Pre-fill the chambers with ECM: 1.5 ml in the lower compartment and 0.5 ml in the upper compartment.</li>
	<li>Wednesday of the second week, wash twice the RBEC with DPBS without calcium and magnesium. Add 4 ml of warm trypsin 0.05% - EDTA 0,02% solution at 37 &#176;C per T75 flask during 30 sec exactly. Then remove 3.5 ml of trypsin solution and observe under the microscope. When the cell layer starts to detach from the matrix, help them by gently tapping the edge of the T75 flask until all the cells are floating.</li>
	<li>Add 9 ml of ECM per T75 flask and transfer into a 15 ml Falcon tube. Very gently dissociate the cell suspension by pipetting up and down 4 times with a 10 ml pipette equipped with a yellow tip (avoid the production of bubbles in the solution). Count the cells in the suspension (approximately 3 x 106 cells/T75) and immediately plate on pre-coated and pre-filled filters at a high density (160 x 103 cells/filter hence approximately 18 filters/T75) (Figure 8). The following day (Thursday), change twice the medium of the upper compartment to remove cell debris.</li>
	<li>Thursday of the second week, the day before the establishment of the co-culture, replace the astrocyte culture media by 1.5 ml of differentiation media (ECM with hydrocortisone at 500 nM) that&#160;can be supplemented with 1/3 conditioned medium from the basal compartment of a previous co-culture (3 days of contact between endothelial cells and astrocytes).</li>
	<li>Friday of the second week is defined as the day 0 of differentiation; replace the culture media from the filters containing the RBEC with differentiation media. Transfer the RBEC filters into the wells containing the astrocytes. Under these conditions, in vitro models differentiate and express junction-related proteins within 3 days.</li>
	<li>The models keep their optimal differentiation during 3 more days, between Monday and Wednesday of the third week.</li>
</ol>

Michel Khrestchatisky is director of the UMR7259 laboratory, co-founder and scientific counsel of VECT-HORUS biotechnology company.

We describe the implementation of a weekly reproducible protocol for the isolation and plating of brain microvessels, following purification and culture of RBEC and further setting up of co-cultures with primary rat astrocytes to generate an in vitro BBB model with characteristic BBB properties.
Successfully establishing standardized in vitro BBB cultures requires optimal conditions in the multiple sequential steps of the process. The model was (a) optimized to obtain the lowest paracellular permeability, which remains the &#8220;Holy grail&#8221; of in vitro BBB models, and (b) validated for efflux and RMT mechanisms.
Production, Purification and Proliferation of RBEC
The greatest challenge when cultivating RBEC is to achieve reproducibility between different cultures. Standardization of the protocol requires high quality tools for dissection, high quality reagents and respect of reagent expiration dates. The experimenter needs to be skilled in micro-dissection under stereomicroscope for rapid removal of meninges and large vessels from the cortex surface. Once the brains are isolated and mechanically dissociated, one of the major challenges is the optimal enzymatic digestion of the freshly isolated brain microvessels. The type and quality of the enzymes used is critical. A mix of collagenases type I and II and dispase at high concentration with low variability between batches was used. Also important are the duration of the enzymatic digestion and the ratio between enzyme concentration/tissue weight/volume of digestion. The best yield of brain microvessel production was obtained with the equivalent of cortices from 1 brain in 1 ml&#160;of collagenases / dispase mix at 60 &#181;g/ml during both digestions, respectively 30 min and 1 hr.
Also critical is the elimination of contaminating cells (astrocytes and mainly pericytes). These cells proliferate at higher rate than endothelial cells and do not establish tight junctions with the latter, thus preventing the establishment of a homogeneous cell monolayer with good paracellular restrictiveness. Considering that brain endothelial cells express much higher levels of efflux pumps, especially P-gp, compared to the other cell types found in microvessels, they tolerate better the otherwise toxic concentrations of P-gp ligand drugs, while non-endothelial cells are eliminated. Puromycin treatment at 4 &#181;g/ml for the first two days was followed by two more days at 2 &#181;g/ml to obtain good endothelial cell purity. This selection can also favor capillary endothelial cells versus those from venules, pre-capillary arterioles or larger microvessels, and lead to tighter monolayers. In addition, the use of poor plasma-derived bovine serum is an imperative to obtain pure cultures of endothelial cells47,48. The plasma-derived serum lacks platelet-derived growth factor (PDGF), which is mitogenic for fibroblasts, for smooth muscle cells and therefore for pericytes.
We observed that treatment of plastic and filters with a mix of collagen type IV from mice and human fibronectin yields a significant advantage, with a 2-fold increase of the proliferation yield in comparison with the traditionally recommended collagen type I from rat tail. Important cues for cell proliferation are provided by the extracellular matrix such as integrin and growth factor (bFGF) activation49. Buffer concentration and pH of the culture media have been described to impact positively on paracellular tightness50 and we observed a better reproducibility between cultures with the addition of HEPES buffer at 5 mM.
Differentiation of RBEC: Co-culture Establishment on Insert Filters
Once brain endothelial cells have been purified and have proliferated for 6 days, they can be plated on filters. Cell plating at high density is critical to obtain a perfect monolayer. A seeding density of 160x103 cells per 12 well plate filters was necessary and sufficient to obtain a confluent monolayer 24 hr after seeding. However, isolation of primary brain capillary endothelial cells from their environment is a paradox in the construction of a BBB in vitro model as it is known that primary cells, and notably brain capillary endothelial cells, are strongly regulated by their environment and inductive factors produced by the different surrounding cell types. Brain capillary endothelial cells cultured alone rapidly de-differentiate and loose some specific brain endothelial markers. Thus, primary endothelial cells should be used at low passage (P1) and re-connected, at least in part, with their environment by co-culture with astrocytes or medium conditioned by astrocytes47,51. This holds true for astrocyte differentiation as brain endothelial cells and astrocytes are involved in two-way induction. Culturing RBEC with astrocytes led to strong induction of interendothelial TJ52,23. The molecular mechanisms of re-induction remain largely unknown, and research is ongoing in several laboratories to identify specific modulating factors secreted by astrocytes, which could promote optimal endothelial cell differentiation53,54. Factors secreted by brain endothelial cells including leukemia inhibitory factor (LIF) have been shown to induce astrocytic differentiation55,56. Before co-culture establishment, astrocytes were exposed to differentiation medium containing the glucocorticoid receptor agonist hydrocortisone, and co-culture conditioned medium. Hydrocortisone is known to improve the tightness of brain endothelial cells and is used in BBB models especially from rat57 and mouse58,59 endothelial cells. The conditioned medium is collected from the lower compartment of the endothelial cell/astrocyte co-culture system after 3 days and frozen for later use. The use of co-culture conditioned medium reduced the time of endothelial cell differentiation to 3 days with optimal paracellular permeability for 2 more days and also improved reproducibility between cultures.
Overall, the protocol we describe yields a reproducible TEER over 300 ohm &#183; cm2&#160;and an average paracellular permeability coefficient Pe(LY) of 0.26 &#177; 0.11&#160;x 10-3 cm/min, similar to the best primary cell-based BBB models22,12. The protocol we describe in the present manuscript with the proposed modulation of microvessel enzymatic digestion can be extended to endothelial cells from the rat spinal cord60 and from mice brain.
Molecular and Functional Characterization
In addition to TJ induction, astrocytes also contribute to the expression of efflux transporters such as P-gp in brain endothelial cells61. We indeed show expression of the efflux transporter P-gp in the BBB model and we demonstrate the polarity of the P-gp efflux pump localization using biochemical approaches, and of P-gp activity using a functional assay. GLT-1 expression was detected in the basal membrane fraction of microvessels but was not detected in cultured RBEC. We hypothesize that GLT-1 was down regulated in our RBEC culture in comparison with in vivo conditions and consequently not detectable by western blot analysis. Excess glutamate is neurotoxic and in vivo, GLT-1 is responsible for glutamate efflux from the basal compartment (parenchyma) to the apical compartment (blood circulation). In astrocyte cultures, GLT-1 expression remains very low and is induced by the addition of glutamate in the medium62,63.
We also confirm the expression of influx transporters at the apical membrane such as LRP1, LDLR and TfR. Functionality of TfR and LDLR was demonstrated with binding and transport experiments of Tf-Cy3 and DiLDL from the luminal to the abluminal side of the monolayer as previously shown with a bovine in vitro BBB model64. Interestingly, it has been shown that lipid requirement from astrocytes increases the expression of LDLR on brain capillary endothelial cells65,66 further confirming the physiological crosstalk between astrocytes and brain endothelial cells, including in vitro. We have chosen to exemplify transport with fluorescent dyes such as Cy3 and DiI considering that spectrofluorimetric analysis is available in most laboratories, and can prove useful to validate in vitro BBB models. However, quantification of fluorescence is far less sensitive than radioactivity and requires an increase in the number of experiments to obtain significant data. Ideally, Tf and LDL are usually radiolabeled (Iodine 125) for such binding/uptake and transport experiments.
We also show that the differentiated endothelial cell monolayer obtained with the proposed protocol responds to inflammation induced by TNF-&#945;, as revealed by CCL2 release and BBB opening. CCL2 (MCP-1) and its receptor CCR2 are involved in CNS pathologies such as multiple sclerosis, experimental autoimmune encephalomyelitis (EAE)67, CNS trauma68 and are known as mediators of leukocyte migration into the CNS under neuroinflammatory conditions69,70. With the tested protocol, we cannot conclude on a polarized secretion of CCL2 because BBB opening allows the CCL2 concentration to equilibrate between both upper (apical) and lower (basal) compartments. Consequently, we clearly underestimate the amount of CCL2 produced by the RBEC in the apical compartment at 24 hr (Figure 5A).
General Overview and Limitations of BBB In Vitro Models: In Vivo versus In Vitro and Rodent versus Human Comparisons
Many promising CNS drugs that proved effective in BBB passage in vitro failed in clinical trials due to lack of predictability from in vitro BBB models often based on cells isolated from other species than human. To the best of our knowledge, the in vitro BBB models are probably more predictive when it comes to studying mechanistic aspects of protein networks, signal transduction, transporters and receptors. Every mechanism, pathway or target to be studied in vitro has to be characterized for its regulation by complementary environmental cues (other cell types, chemicals, proteins)&#160;and combined to in situ studies with the same animal species, and when possible, with microvessels and endothelial cells isolated from humans, with the restrictions and caution evoked below.
In vitro BBB models have to be seen as autonomous systems, isolated from body regulation, but still endowed with major in vivo properties and a potential for regulation by environmental cues. No &#8220;ideal&#8221; in vitro BBB model has been proposed yet71,72,73 because the endothelial cell monolayers lack a number of important constituents of the neuro-glia vascular unit (NGVU) and are isolated from blood and body regulation. The lack of pericytes74,16 or neurons17,18 or the different constituents of the extracellular matrix used for plastic coating or the culture medium and serum used for cell growth in the most common and &#8220;easiest made&#8221; in vitro BBB models based on endothelial cells differentiated with astrocytes may modulate protein expression in comparison with the in vivo situation75. These models may express many transporters displayed in vivo, but not all. In some cases, transport parameters were first verified in isolated microvessels (closest to the in vivo situation), and then studied in cell culture systems76,61.
Molecular biology research has allowed the characterization of gene and protein expression in isolated microvessels and low passage endothelial cell cultures from the same species, and between different species, most often from small animals such as rodents (mice and rats) or from cow and pig in comparison to humans77,78,75,15. Transcriptomic comparison between in vivo and in vitro brain microvascular endothelial cells showed numerous gene transcripts that were differentially expressed and most often significantly downregulated in vitro. Transcripts encoding influx transporters such as TfR and proteins implicated in vesicle trafficking are mainly downregulated in cultured brain endothelial cells, suggesting a general decrease in endocytosis and vesicular transport in such cells. Culture manipulation in terms of purity (puromycin treatment) and treatment with hydrocortisone may help to restore a more &#8220;in vivo-like&#8221; gene expression profile77. Transcriptomic studies also revealed important differences between species that further complicate predictions on drug uptake in humans based on rodent in vitro BBB models75. In vitro BBB models involving co-culture of human endothelial cells and astrocytes have been described15. Although relevant, these models are more difficult to implement on a regular basis as they require regulated access to post-mortem human tissue and there is heterogeneity in the quality/properties of the human brain endothelial cells depending on the age, diseases, and possibly medical treatment of donors. Efforts have to be made to develop new in vitro models that better reproduce the physiological, anatomical and functional characteristics of the in vivo BBB. Co-cultures involving three-cell types are highly restrictive and appear difficult to implement routinely. To date, the most complex in vitro BBB models are the dynamic in vitro models (DIV-BBB) which include vessel-like organization with astrocytes and include a flow of medium that mimics the blood flow 75,79,80,81,82,83,84,85. When cerebral endothelial cells are exposed to a flow, the generated shear stress activates mechanotransducers at the cell surface, which modulate the expression of different genes involved in endothelial cell physiology such as cell division, differentiation, migration and apoptosis80. In vivo, shear stress generated by the blood flow is responsible for mitotic arrest at the cell contact, which permits the establishment of an endothelial cell monolayer in blood vessels80. Genomic and proteomic analysis of normal human brain microvascular endothelial cells showed the impact of shear stress in BBB endothelial physiology84. Shear stress is responsible for cell survival, a higher degree of endothelial cell adhesion, efflux pump induction and better polarization of transporters75, regulation of glucose metabolism75,86, oxidation mediated by CYP450 enzymes75 and the regulation of paracellular permeability by increasing the expression of genes encoding for intercellular junctional elements like occludin and ZO-187,75,80 and consequently high TEER around 1,500 - 2,000 ohm &#183; cm2, the closest to known in vivo parameters79,80
In the biotechnology and pharmaceutical industry, routine screening of drugs or even high throughput screening (HTS) and efforts to reduce animal experimentation, led to the development of different cell lines to be used in replacement of the primary culture of cerebral endothelial cells which remain more difficult to set-up routinely. In most cases, primary cultures of cerebral endothelial cells were transduced with an immortalizing gene (SV40 or polyoma virus large T-antigen or adenovirus E1A), either by transfection of plasmid DNA or by infection using retroviral vectors88,89,75. Several endothelial cell lines of cerebral origin have been developed such as the RBE4, GP8/3.9, GPNT, RBEC1, TR-BBBs or rBCEC4 rat cell lines88,75, the b.End3 mouse cell line90,75, the PBMEC/C1&#8211;2 porcine cell line87,75, and the hCMEC/D3 human cell line89,75. Other models are based on cells of non-cerebral origin such as the Madin-Darby canine kidney (MDCK) or Caco2 cell lines12,75. Among the different human cerebral endothelial cell lines, the hCMEC/D3 has been widely cited and improved as a model of BBB since its establishment in 200591,92. Like primary cultures, cell lines present advantages and limitations. They are easier to handle than primary cultures, have an extended life span, are well characterized and allow reproducibility between large scale experiments. However, cell lines can lose tissue-specific functions, lose environmental regulation and acquire a molecular phenotype quite different from cells in vivo75,89. In particular, monolayers generated from cell lines present reduced tightness, low TEER and show transporter profile variation75,89. Thus animal experiments or studies in primary cells are often preferred despite their added complexity.

Many drugs developed to treat Central Nervous System (CNS) disorders are unable to reach the brain parenchyma in therapeutically relevant concentrations. The BBB protects brain nervous tissue from the fluctuation of plasma composition, from pathogenic agents, and maintains homeostasis of the brain parenchyma by restricting non-specific flux of ions, peptides, proteins and even cells into and out the brain1.
BBB characteristics are induced and maintained by intimate proximity and cross-talk between the specialized class brain microvessel endothelial cells and neighboring elements of the neuro-glia-vascular unit (NGVU) such as neurons, glial cells (more precisely astrocyte end-feet), and pericytes ensheathed in the basal membrane which consists mainly of collagen type IV, fibronectin, laminin and proteoglycans2,3. Pericytes cover approximately 22 - 32% of the endothelium at the capillary level and play an important role in the regulation of endothelium proliferation, angiogenesis and inflammatory processes. Endothelial cells form a continuous sheet covering the inner surface of the capillaries. They are interconnected by TJs, which form a belt-like structure at the apical region and that contribute to cell polarization. Astrocytes regulate BBB properties and are sources of important regulatory factors such as TGF-&#946;, GDNF, bFGF and IL-6. Astrocytes deficient in GFAP with incomplete functionality are not able to regulate BBB properties4. Neurons are not directly involved structurally in the formation of the BBB but also regulate important aspects of protein expression and BBB functions5.
In order to further study the structure, physiology and pathology of the BBB, in vitro models of the BBB were developed as research tools. Brain endothelial cells have been extracted from various species to implement in vitro BBB models based on low passage primary cultures from bovine6,7, porcine8,9, rat10,11,12, mouse13 and also human14,15. These models are known to mimic the in vivo BBB, particularly when co-cultured with glial cells from rat or murine and/or pericytes16,12, and/or neural progenitor cell-derived astrocytes17 and/or neurons18. The &#8220;in lab&#8221; models are often produced from rodents because they allow in vitro / in vivo experiments and comparisons and/or the study of brain endothelial cells produced from transgenic models19.
Newly developed in vitro BBB models have also been designed to help predict brain uptake of potential CNS drug candidates prior to in vivo testing15,20,21,3,6,22,11,23. In vitro BBB models are usually used to compare the transport of drugs with: i) known penetration into the CNS or with low permeability across the BBB and no central effects, and ii) the apparent Pe of the same drugs measured in animal models of the same species. The drugs that readily pass the BBB are mostly lipophilic and cross the brain endothelial cell membranes by lipid-mediated free diffusion (caffeine, carbamazepine, etc.). The negatively transported drugs such as digoxin, verapamil or cyclosporine A are actively extruded by brain endothelial efflux transporters such as P-gp. However, many of the newly developed therapeutic molecules are biopharmaceuticals, such as recombinant proteins, siRNAs or monoclonal antibodies. Most of them do not cross the BBB due to: i) the absence of specific transporters, and ii) the tightly packed layer of endothelial cells, which prevent high molecular weight molecules from undergoing paracellular passage. With these limits, &#8220;Trojan horse&#8221; strategies have been implemented using vectors (antibodies, peptides) against known receptors at the BBB, involved in receptor mediated transport or transcytosis (RMT), such as the transferrin (Tf) receptor (TfR), the Insulin receptor (IR), or members of the LDL receptor (LDLR)-related receptor family (LDLR, LRP1). Such receptors have been found on isolated brain capillaries and in the BBB in vivo24,25. Transcriptional profiles for these receptors, in particular those of the LDLR family, were analyzed and compared between brain endothelial cells and brain endothelial cells co-cultured with astrocytes or in brain capillaries directly after their extraction from brain26. Pardridge24 opened the field with the OX-26 antibody against the transferrin receptor (TfR), followed by antibodies against the insulin receptor and the insulin growth factor receptor27,28. With&#160;these antibody based vectors, ArmaGen Technologies has developed a BBB molecular Trojan horse platform technology to deliver drugs, including proteins, across the BBB29. The literature is rich in data showing LRP1 expression in brain endothelial cells and its role as a powerful endocytic/scavenger receptor. Western blot analysis suggested that LRP1 is expressed in fractions enriched in brain capillaries and in rat brain capillary endothelial cells30. Companies such as Angiochem target LRP1 with peptide vectors derived from aprotinin that promote efficient drug influx across the BBB31. However, LRP1 is also involved in active transport of A&#946;&#160;and its efflux/clearance from brain parenchyma to blood32. Such data involve LRP1 in a bi-directional transport across the BBB depending on its ligands. biOasis develops the Transcend technology using a protein melanotransferrin for the transport of biologics such as lysosomal enzymes and antibodies across the BBB33 while VECT-HORUS develops peptide vectors that target the LDLR34. There is data suggesting that the LRP and LDLR can be used to transport different molecules such as lysosomal enzymes35,36 or nanoparticle complexes across the BBB37.
Our field of interest is drug delivery to the CNS using vector molecules and vectorized drug-candidates for the treatment of CNS diseases. In particular, drug delivery across the BBB has to be considered within the context of neuroinflammation, a process that may vary in its extent, but that is probably common to all CNS lesions and diseases, including encephalitis, multiple sclerosis, Alzheimer&#8217;s disease etc. Neuroinflammation is associated with BBB inflammation and potentially with changes in BBB physiology and permeability considering that paracellular and transcellular transport can be amplified in pathological conditions38,39,40,41,42,43. For instance, TNF-&#945;, TWEAK, and other cytokines modulate inflammation, and experiments with in vitro BBB models have shown that they can alter the paracellular properties of the endothelial cell monolayer38,39,40 and that TNF-&#945; also leads to an increase in transcellular transport of LDL41, holotransferrin42 and lactoferrin43.
Our objective was to develop and characterize an optimized and highly reproducible rat syngeneic BBB model using co-cultures of primary brain endothelial cells and astrocytes. We used 5 week old and neonatal Wistar rats for brain endothelial cell production and astrocyte production respectively. One challenge was to establish a protocol allowing the production of &#8220;weekly reproducible&#8221; BBB models. To reach this objective, every step of the production protocol was performed on fixed days of the week, starting from brain microvessel production on Wednesday of the first week. Dissections were performed nearly every week during the last 3 years. To further improve the reproducibility of the cultures, a quality assurance system was established. All reagents and chemicals were referenced in a database (date of entry, stock, expiration term, etc.).
The model was characterized following a number of criteria, such as endothelial cell organization and purity, TEER, LY permeability, response to pro-inflammatory agents, qualitative and quantitative expression of TJ proteins, functionality of efflux transporters such as P-gp, and receptors involved in transcytosis across the endothelial cell monolayer such as the TfR or the LDLR.

<table border="0" cellpadding="0" cellspacing="0" width="666">
	<tbody>
		<tr height="43">
			<td height="43" style="height:43px;width:189px;">Product</td>
			<td style="width:149px;">Company</td>
			<td style="width:153px;">Catalog Number</td>
			<td style="width:175px;">Comments / expiration term</td>
		</tr>
		<tr height="43">
			<td height="43" style="height:43px;width:189px;">BSA fraction V low endotoxin</td>
			<td style="width:149px;">PAA</td>
			<td style="width:153px;">K45-011-500g</td>
			<td style="width:175px;">4 &#176;C&#160;</td>
		</tr>
		<tr height="33">
			<td height="33" style="height:33px;width:189px;">Penicillin-Streptomycin</td>
			<td style="width:149px;">Invitrogen</td>
			<td style="width:153px;">15140-122</td>
			<td style="width:175px;">&#160;- 20 &#176;C</td>
		</tr>
		<tr height="38">
			<td height="38" style="height:39px;width:189px;">0,05% Trypsin-EDTA (1X)</td>
			<td style="width:149px;">Invitrogen</td>
			<td style="width:153px;">25300-054</td>
			<td style="width:175px;">&#160;- 20 &#176;C</td>
		</tr>
		<tr height="33">
			<td height="33" style="height:33px;width:189px;">DMEM High Glucose</td>
			<td style="width:149px;">Invitrogen</td>
			<td style="width:153px;">61965-026</td>
			<td style="width:175px;">4 &#176;C&#160;</td>
		</tr>
		<tr height="36">
			<td height="36" style="height:36px;width:189px;">Fetal Bovine Serum</td>
			<td style="width:149px;">Invitrogen</td>
			<td style="width:153px;">10270-098</td>
			<td style="width:175px;">&#160;- 20 &#176;C / 1 year</td>
		</tr>
		<tr height="46">
			<td height="46" style="height:47px;width:189px;">T75 flasks</td>
			<td style="width:149px;">Becton Dickinson Falcon</td>
			<td style="width:153px;">353135</td>
			<td style="width:175px;"></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:43px;width:189px;">HEPES buffer (1 M)</td>
			<td style="width:149px;">Invitrogen</td>
			<td style="width:153px;">15630-056</td>
			<td style="width:175px;">4 &#176;C / 1 year</td>
		</tr>
		<tr height="50">
			<td height="50" style="height:51px;width:189px;">Collagene type IV mouse (10 x 1 mg)</td>
			<td style="width:149px;">Becton Dickinson</td>
			<td style="width:153px;">356233</td>
			<td style="width:175px;">&#160;- 20 &#176;C / 1 month</td>
		</tr>
		<tr height="48">
			<td height="48" style="height:48px;width:189px;">Fibronectin humain plasma (5 mg)</td>
			<td style="width:149px;">Becton Dickinson</td>
			<td style="width:153px;">356008</td>
			<td style="width:175px;">&#160;- 20 &#176;C / 1 month</td>
		</tr>
		<tr height="46">
			<td height="46" style="height:47px;width:189px;">Vannas Spring Scissors, straight (9 cm)</td>
			<td style="width:149px;">Fine Science Tools</td>
			<td style="width:153px;">91500-09</td>
			<td style="width:175px;"></td>
		</tr>
		<tr height="46">
			<td height="46" style="height:47px;width:189px;">Scissors, straight (9 cm)</td>
			<td style="width:149px;">Fine Science Tools</td>
			<td style="width:153px;">14568-09</td>
			<td style="width:175px;"></td>
		</tr>
		<tr height="46">
			<td height="46" style="height:47px;width:189px;">Forceps Dumont #5/45 (11 cm)</td>
			<td style="width:149px;">Fine Science Tools</td>
			<td style="width:153px;">11251-35</td>
			<td style="width:175px;"></td>
		</tr>
		<tr height="46">
			<td height="46" style="height:47px;width:189px;">Graefe Forceps, tip width 0,8 mm</td>
			<td style="width:149px;">Fine Science Tools</td>
			<td style="width:153px;">11050-10</td>
			<td style="width:175px;"></td>
		</tr>
		<tr height="46">
			<td height="46" style="height:47px;width:189px;">Graefe Forceps, curve tip width 0,8 mm</td>
			<td style="width:149px;">Fine Science Tools</td>
			<td style="width:153px;">11051-10</td>
			<td style="width:175px;"></td>
		</tr>
		<tr height="50">
			<td height="50" style="height:51px;width:189px;">Collagenases / Dispase mix (2 x 5 mg)</td>
			<td style="width:149px;">Roche Diagnostics</td>
			<td style="width:153px;">05 401 054 001</td>
			<td style="width:175px;">- 20 &#176;C / 3 months</td>
		</tr>
		<tr height="52">
			<td height="52" style="height:52px;width:189px;">DNase I (100 mg / 569 KU / mg)</td>
			<td style="width:149px;">Sigma Aldrich</td>
			<td style="width:153px;">DN25-100 mg</td>
			<td style="width:175px;">&#160;- 20 &#176;C / 1 year</td>
		</tr>
		<tr height="37">
			<td height="37" style="height:37px;width:189px;">Gentamicin (10 mg/mL)</td>
			<td style="width:149px;">Invitrogen</td>
			<td style="width:153px;">15710-049</td>
			<td style="width:175px;">4 &#176;C / 1 year</td>
		</tr>
		<tr height="37">
			<td height="37" style="height:37px;width:189px;">DMEM/F12</td>
			<td style="width:149px;">Invitrogen</td>
			<td style="width:153px;">31331-028</td>
			<td style="width:175px;">4 &#176;C&#160;</td>
		</tr>
		<tr height="49">
			<td height="49" style="height:49px;width:189px;">Bovine serum from platelet poor plasma (500 mL)</td>
			<td style="width:149px;">Clinisciences</td>
			<td style="width:153px;">BT-214-100</td>
			<td style="width:175px;">&#160;- 20 &#176;C / 1 year</td>
		</tr>
		<tr height="44">
			<td height="44" style="height:44px;width:189px;">bFGF (10 &#181;g)</td>
			<td style="width:149px;">Invitrogen</td>
			<td style="width:153px;">13256-029</td>
			<td style="width:175px;">&#160;- 20 &#176;C / 6 months</td>
		</tr>
		<tr height="49">
			<td height="49" style="height:49px;width:189px;">Heparine Na salt from porcine mucosa Grade I</td>
			<td style="width:149px;">Sigma Aldrich</td>
			<td style="width:153px;">H3149-100KU</td>
			<td style="width:175px;">4 &#176;C / 1 year</td>
		</tr>
		<tr height="37">
			<td height="37" style="height:37px;width:189px;">Puromycin</td>
			<td style="width:149px;">Sigma Aldrich</td>
			<td style="width:153px;">P8833-10 mg</td>
			<td style="width:175px;">&#160;- 20 &#176;C / 6 months</td>
		</tr>
		<tr height="37">
			<td height="37" style="height:37px;width:189px;">ITSX</td>
			<td style="width:149px;">Invitrogen</td>
			<td style="width:153px;">51500-056</td>
			<td style="width:175px;">4 &#176;C / 1 year</td>
		</tr>
		<tr height="50">
			<td height="50" style="height:51px;width:189px;">Polyethylene hanging cell insert for 12-well plates</td>
			<td style="width:149px;">Millipore</td>
			<td style="width:153px;">PIRP15R48</td>
			<td style="width:175px;">Porosity: 1 &#181;m 
			Surface: 1,1 cm2</td>
		</tr>
		<tr height="46">
			<td height="46" style="height:47px;width:189px;">Hydrocortisone</td>
			<td style="width:149px;">Sigma Aldrich</td>
			<td style="width:153px;">H0888-1 g</td>
			<td style="width:175px;">&#160;- 20 &#176;C / 1 year</td>
		</tr>
		<tr height="37">
			<td height="37" style="height:37px;width:189px;">Mouse anti-CD31 / PECAM&#160;</td>
			<td style="width:149px;">Chemicon</td>
			<td style="width:153px;">MAB1393, clone TLD-3A12 (1 mg/mL)</td>
			<td style="width:175px;">1/200 - fixation PFA 4%</td>
		</tr>
		<tr height="42">
			<td height="42" style="height:43px;width:189px;">Rabbit anti-Von Willebrand</td>
			<td style="width:149px;">Chemicon</td>
			<td style="width:153px;">AB7356</td>
			<td style="width:175px;">1/200 - fixation PFA 4%</td>
		</tr>
		<tr height="48">
			<td height="48" style="height:48px;width:189px;">Mouse anti-Desmine</td>
			<td style="width:149px;">Chemicon</td>
			<td style="width:153px;">MAB3430</td>
			<td style="width:175px;">1/200 - fixation PFA 4%</td>
		</tr>
		<tr height="48">
			<td height="48" style="height:48px;width:189px;">Mouse anti-Vimentine</td>
			<td style="width:149px;">Invitrogen, Zymed</td>
			<td style="width:153px;">08-0052 clone V9, (58 &#181;g/mL)&#160;</td>
			<td style="width:175px;">1/50 - fixation PFA 4%</td>
		</tr>
		<tr height="48">
			<td height="48" style="height:48px;width:189px;">Mouse anti-Claudin-5</td>
			<td style="width:149px;">Invitrogen, Zymed</td>
			<td style="width:153px;">35-2500, (500 &#181;g/mL)</td>
			<td style="width:175px;">1/200 - fixation PFA 4%</td>
		</tr>
		<tr height="46">
			<td height="46" style="height:47px;width:189px;">Rabbit anti-ZO-1</td>
			<td style="width:149px;">Invitrogen, Zymed</td>
			<td style="width:153px;">61-7300 (250 &#181;g/mL)</td>
			<td style="width:175px;">1/200 - fixation PFA 4%</td>
		</tr>
		<tr height="45">
			<td height="45" style="height:45px;width:189px;">Rabbit anti-Occludine&#160;</td>
			<td style="width:149px;">Invitrogen, Zymed</td>
			<td style="width:153px;">71-1500 (250 &#181;g/mL)</td>
			<td style="width:175px;">1/200 - fixation PFA 4%</td>
		</tr>
		<tr height="72">
			<td height="72" style="height:72px;width:189px;">Alexa fluor 488, 594 conjugated secondary antibodies</td>
			<td style="width:149px;">Invitrogen</td>
			<td style="width:153px;"></td>
			<td style="width:175px;">1/800</td>
		</tr>
		<tr height="46">
			<td height="46" style="height:47px;width:189px;">Lucifer yellow CH, dilithium salt</td>
			<td style="width:149px;">Sigma Aldrich</td>
			<td style="width:153px;">L0259</td>
			<td style="width:175px;">&#160;- 20 &#176;C</td>
		</tr>
		<tr height="33">
			<td height="33" style="height:33px;width:189px;">TNF-a Human</td>
			<td style="width:149px;">PeproTech</td>
			<td style="width:153px;">300-01A</td>
			<td style="width:175px;">&#160;- 20 &#176;C</td>
		</tr>
		<tr height="48">
			<td height="48" style="height:48px;width:189px;">Rat MCP-1 ELISA Kit</td>
			<td style="width:149px;">PeproTech</td>
			<td style="width:153px;">900-K59</td>
			<td style="width:175px;">4 &#176;C / - 20 &#176;C</td>
		</tr>
		<tr height="49">
			<td height="49" style="height:49px;width:189px;">Mouse anti-P-glycoprotein</td>
			<td style="width:149px;">Covance, Eurogentec</td>
			<td style="width:153px;">SIG-38710-1000, clone C219 (1mg/mL)</td>
			<td style="width:175px;">1/400 - fixation PFA 4% 
			1/200 (western blot)</td>
		</tr>
		<tr height="52">
			<td height="52" style="height:52px;width:189px;">Rabbit anti-GLT-1</td>
			<td style="width:149px;">Abcam</td>
			<td style="width:153px;">ab41621</td>
			<td style="width:175px;">1/1000 (western blot)</td>
		</tr>
		<tr height="52">
			<td height="52" style="height:52px;width:189px;">Rhodamine 123</td>
			<td style="width:149px;">Sigma Aldrich</td>
			<td style="width:153px;">83702</td>
			<td style="width:175px;">4 &#176;C</td>
		</tr>
		<tr height="52">
			<td height="52" style="height:52px;width:189px;">Verapamil hydrochloride</td>
			<td style="width:149px;">Sigma Aldrich</td>
			<td style="width:153px;">V4629</td>
			<td style="width:175px;">4 &#176;C</td>
		</tr>
		<tr height="52">
			<td height="52" style="height:52px;width:189px;">Cyclosporine A</td>
			<td style="width:149px;">Sigma Aldrich</td>
			<td style="width:153px;">30024</td>
			<td style="width:175px;">4 &#176;C</td>
		</tr>
		<tr height="122">
			<td height="122" style="height:123px;width:189px;">Monoclonal anti a2 Macroglobulin Receptor (CD91, LRP1) against b-chain of amino acid 4291-4344 within an EGF repeat</td>
			<td style="width:149px;">American Diagnostica</td>
			<td style="width:153px;">3501 (100 &#181;g/mL)</td>
			<td style="width:175px;">1/5 - fixation PFA 4%</td>
		</tr>
		<tr height="37">
			<td height="37" style="height:37px;width:189px;">Mouse anti-LDLR</td>
			<td style="width:149px;">R&#38;D systems</td>
			<td style="width:153px;">AF2255 (200 &#181;g/mL)</td>
			<td style="width:175px;">1/50 - fixation PFA 4%</td>
		</tr>
		<tr height="33">
			<td height="33" style="height:33px;width:189px;">Rat transferrin-Cy3</td>
			<td style="width:149px;">Gentaur</td>
			<td style="width:153px;">JOR160050</td>
			<td style="width:175px;">4 &#176;C</td>
		</tr>
		<tr height="37">
			<td height="37" style="height:37px;width:189px;">DiILDL</td>
			<td style="width:149px;">Invitrogen</td>
			<td style="width:153px;">L-3482</td>
			<td style="width:175px;">4 &#176;C</td>
		</tr>
	</tbody>
</table>

setting-up an in vitro model of rat blood-brain barrier (bbb): a focus on bbb impermeability and receptor-mediated transport

The blood brain barrier (BBB) specifically regulates molecular and cellular flux between the blood and the nervous tissue. Our aim was to develop and characterize a highly reproducible rat syngeneic in vitro model of the BBB using co-cultures of primary rat brain endothelial cells (RBEC) and astrocytes to study receptors involved in transcytosis across the endothelial cell monolayer. Astrocytes were isolated by mechanical dissection following trypsin digestion and were frozen for later co-culture. RBEC were isolated from 5-week-old rat cortices. The brains were cleaned of meninges and white matter, and mechanically dissociated following enzymatic digestion. Thereafter, the tissue homogenate was centrifuged in bovine serum albumin to separate vessel fragments from nervous tissue. The vessel fragments underwent a second enzymatic digestion to free endothelial cells from their extracellular matrix. The remaining contaminating cells such as pericytes were further eliminated by plating the microvessel fragments in puromycin-containing medium. They were then passaged onto filters for co-culture with astrocytes grown on the bottom of the wells. RBEC expressed high levels of tight junction (TJ) proteins such as occludin, claudin-5 and ZO-1 with a typical localization at the cell borders. The transendothelial electrical resistance (TEER) of brain endothelial monolayers, indicating the tightness of TJs reached 300 ohm&#183;cm2 on average. The endothelial permeability coefficients (Pe) for lucifer yellow (LY) was highly reproducible with an average of 0.26 &#177;&#160;0.11 x 10-3 cm/min. Brain endothelial cells organized in monolayers expressed the efflux transporter P-glycoprotein (P-gp), showed a polarized transport of rhodamine 123, a ligand for P-gp, and showed specific transport of transferrin-Cy3 and DiILDL across the endothelial cell monolayer. In conclusion, we provide a protocol for setting up an in vitro BBB model that is highly reproducible due to the quality assurance methods, and that is suitable for research on BBB transporters and receptors.

Watch this Scientific Journal Video about Setting-up an In Vitro Model of Rat Blood-brain Barrier BBB: A Focus on BBB Impermeability and Receptor-mediated Transport at JoVE.com

Setting-up an In Vitro Model of Rat Blood-brain Barrier BBB: A Focus on BBB Impermeability and Receptor-mediated Transport

The aim of the present study was to validate the reproducibility of an in vitro BBB model involving a rat syngeneic co-culture of endothelial cells and astrocytes. The endothelial cell monolayer presented high TEER and low LY permeability. Expression of specific TJ proteins, functional responses to inflammation and functionality of transporters and receptors were assessed.

Setting-up an In Vitro Model of Rat Blood-brain Barrier (BBB): A Focus on BBB Impermeability and Receptor-mediated Transport

The blood brain barrier (BBB) specifically regulates molecular and cellular flux between the blood and the nervous tissue. Our aim was to develop and ...

setting-up-an-vitro-model-rat-blood-brain-barrier-bbb-focus-on-bbb

Research

JoVE Journal

Medicine

MRI-guided Disruption of the Blood-brain Barrier using Transcranial Focused Ultrasound in a Rat Model

Focused ultrasound (FUS) disruption of the blood-brain barrier (BBB) is an increasingly investigated technique for circumventing the BBB1-5. The BBB is a significant obstacle to pharmaceutical treatments of brain disorders as it limits the passage of molecules from the vasculature into the brain tissue to molecules less than approximately 500 Da in size6. FUS induced BBB disruption (BBBD) is temporary and reversible4 and has an advantage over chemical means of inducing BBBD by being highly localized. FUS induced BBBD provides a means for investigating the effects of a wide range of therapeutic agents on the brain, which would not otherwise be deliverable to the tissue in sufficient concentration. While a wide range of ultrasound parameters have proven successful at disrupting the BBB2,5,7, there are several critical steps in the experimental procedure to ensure successful disruption with accurate targeting. This protocol outlines how to achieve MRI-guided FUS induced BBBD in a rat model, with a focus on the critical animal preparation and microbubble handling steps of the experiment.

Microbubble-mediated focused ultrasound disruption of the blood-brain barrier (BBB) is a promising technique for non-invasive targeted drug delivery in the brain1-3. This protocol outlines the experimental procedure for MRI-guided transcranial BBB disruption in a rat model.

Focused ultrasound (FUS) disruption of the blood-brain barrier (BBB) is an increasingly investigated technique for circumventing the BBB1-5. The BBB is a ...

Rat Model of Blood-brain Barrier Disruption to Allow Targeted Neurovascular Therapeutics

Endothelial cells with tight junctions along with the basement membrane and astrocyte end feet surround cerebral blood vessels to form the blood-brain barrier1. The barrier selectively excludes molecules from crossing between the blood and the brain based upon their size and charge. This function can impede the delivery of therapeutics for neurological disorders. A number of chemotherapeutic drugs, for example, will not effectively cross the blood-brain barrier to reach tumor cells2. Thus, improving the delivery of drugs across the blood-brain barrier is an area of interest.
The most prevalent methods for enhancing the delivery of drugs to the brain are direct cerebral infusion and blood-brain barrier disruption3. Direct intracerebral infusion guarantees that therapies reach the brain; however, this method has a limited ability to disperse the drug4. Blood-brain barrier disruption (BBBD) allows drugs to flow directly from the circulatory system into the brain and thus more effectively reach dispersed tumor cells. Three methods of barrier disruption include osmotic barrier disruption, pharmacological barrier disruption, and focused ultrasound with microbubbles. Osmotic disruption, pioneered by Neuwelt, uses a hypertonic solution of 25% mannitol that dehydrates the cells of the blood-brain barrier causing them to shrink and disrupt their tight junctions. Barrier disruption can also be accomplished pharmacologically with vasoactive compounds such as histamine5 and bradykinin6. This method, however, is selective primarily for the brain-tumor barrier7. Additionally, RMP-7, an analog of the peptide bradykinin, was found to be inferior when compared head-to-head with osmotic BBBD with 25% mannitol8. Another method, focused ultrasound (FUS) in conjunction with microbubble ultrasound contrast agents, has also been shown to reversibly open the blood-brain barrier9. In comparison to FUS, though, 25% mannitol has a longer history of safety in human patients that makes it a proven tool for translational research10-12.
In order to accomplish BBBD, mannitol must be delivered at a high rate directly into the brain's arterial circulation. In humans, an endovascular catheter is guided to the brain where rapid, direct flow can be accomplished. This protocol models human BBBD as closely as possible. Following a cut-down to the bifurcation of the common carotid artery, a catheter is inserted retrograde into the ECA and used to deliver mannitol directly into the internal carotid artery (ICA) circulation. Propofol and N2O anesthesia are used for their ability to maximize the effectiveness of barrier disruption13. If executed properly, this procedure has the ability to safely, effectively, and reversibly open the blood-brain barrier and improve the delivery of drugs that do not ordinarily reach the brain 8,13,14.

Blood-brain barrier disruption aids the delivery of certain drugs to the brain. Mannitol delivered intra-arterially shrinks cells surrounding blood vessels in order to physically disrupt the barrier.

Endothelial cells with tight junctions along with the basement membrane and astrocyte end feet surround cerebral blood vessels to form the blood-brain ...

Stretch in Brain Microvascular Endothelial Cells (cEND) as an In Vitro Traumatic Brain Injury Model of the Blood Brain Barrier

Due to the high mortality incident brought about by traumatic brain injury (TBI), methods that would enable one to better understand the underlying mechanisms involved in it are useful for treatment. There are both in vivo and in vitro methods available for this purpose. In vivo models can mimic actual head injury as it occurs during TBI. However, in vivo techniques may not be exploited for studies at the cell physiology level. Hence, in vitro methods are more advantageous for this purpose since they provide easier access to the cells and the extracellular environment for manipulation.
Our protocol presents an in vitro model of TBI using stretch injury in brain microvascular endothelial cells. It utilizes pressure applied to the cells cultured in flexible-bottomed wells. The pressure applied may easily be controlled and can produce injury that ranges from low to severe. The murine brain microvascular endothelial cells (cEND) generated in our laboratory is a well-suited model for the blood brain barrier (BBB) thus providing an advantage to other systems that employ a similar technique. In addition, due to the simplicity of the method, experimental set-ups are easily duplicated. Thus, this model can be used in studying the cellular and molecular mechanisms involved in TBI at the BBB.

Stretch in Brain Microvascular Endothelial Cells cEND as an In Vitro Traumatic Brain Injury Model of the Blood Brain Barrier

In vitro traumatic brain injury models are being developed to reproduce in vivo brain deformation. Stretch-induced injury has been employed for astrocytes, neurons, glial cells, aortic, and brain endothelial cells. However, our system uses a blood brain barrier (BBB) model that possesses properties constituting a legitimate model of the BBB to establish an in vitro&#160;TBI model.

Due to the high mortality incident brought about by traumatic brain injury (TBI), methods that would enable one to better understand the underlying ...

Excitotoxic Stimulation of Brain Microslices as an In vitro Model of Stroke

Examining molecular mechanisms involved in neuropathological conditions, such as ischemic stroke, can be difficult when using whole animal systems. As such, primary or &#39;neuronal-like&#39; cell culture systems are commonly utilized. While&#160;these systems are relatively easy to work with, and are useful model systems in which various functional outcomes (such as cell death) can be readily quantified, the examined outcomes and pathways in cultured immature neurons (such as excitotoxicity-mediated cell death pathways) are not necessarily the same as those observed in mature brain, or in intact tissue. Therefore, there is the need to develop models in which cellular mechanisms in mature neural tissue can be examined. We have developed an in vitro technique that can be used to investigate a variety of molecular pathways in intact nervous tissue. The technique described herein utilizes rat cortical tissue, but this technique can be adapted to use tissue from a variety of species (such as mouse, rabbit, guinea pig, and chicken) or brain regions (for example, hippocampus, striatum, etc.). Additionally, a variety of stimulations/treatments can be used (for example, excitotoxic, administration of inhibitors, etc.). In conclusion, the brain slice model described herein can be used to examine a variety of molecular mechanisms involved in excitotoxicity-mediated brain injury.

Excitotoxic Stimulation of Brain Microslices as an In vitro Model of Stroke

We have developed a brain slice model which can be used to examine molecular mechanisms involved in excitotoxicity-mediated brain injury.&#160;This technique generates viable mature brain tissue and reduces animal numbers required for experimentation, whilst keeping the neuronal circuitry, cellular interactions, and postsynaptic compartments partly intact.

Examining molecular mechanisms involved in neuropathological conditions, such as ischemic stroke, can be difficult when using whole animal systems. As ...

Oxygen-Glucose Deprivation and Reoxygenation as an In Vitro Ischemia-Reperfusion Injury Model for Studying Blood-Brain Barrier Dysfunction

Ischemia-Reperfusion (IR) injury is known to contribute significantly to the morbidity and mortality associated with ischemic strokes. Ischemic cerebrovascular accidents account for 80% of all strokes. A common cause of IR injury is the rapid inflow of fluids following an acute/chronic occlusion of blood, nutrients, oxygen to the tissue triggering the formation of free radicals.
Ischemic stroke is followed by blood-brain barrier (BBB) dysfunction and vasogenic brain edema. Structurally, tight junctions (TJs) between the endothelial cells play an important role in maintaining the integrity of the blood-brain barrier (BBB). IR injury is an early secondary injury leading to a non-specific, inflammatory response. Oxidative and metabolic stress following inflammation triggers secondary brain damage including BBB permeability and disruption of tight junction (TJ) integrity.
Our protocol presents an in vitro example of oxygen-glucose deprivation and reoxygenation (OGD-R) on rat brain endothelial cell TJ integrity and stress fiber formation. Currently, several experimental in vivo models are used to study the effects of IR injury; however they have several limitations, such as the technical challenges in performing surgeries, gene dependent molecular influences and difficulty in studying mechanistic relationships. However, in vitro models may aid in overcoming many of those limitations. The presented protocol can be used to study the various molecular mechanisms and mechanistic relationships to provide potential therapeutic strategies. However, the results of in vitro studies may differ from standard in vivo studies and should be interpreted with caution.

Oxygen-Glucose Deprivation and Reoxygenation as an In Vitro Ischemia-Reperfusion Injury Model for Studying Blood-Brain Barrier Dysfunction

Ischemia-Reperfusion (IR) injury is associated with a high rate of morbidity and mortality. The goal of the in vitro model of oxygen-glucose deprivation and reoxygenation (OGD-R) described here is to assess the effects of ischemia reperfusion injury on a variety of cells, particularly in blood-brain barrier (BBB) endothelial cells.

Ischemia-Reperfusion (IR) injury is known to contribute significantly to the morbidity and mortality associated with ischemic strokes. Ischemic ...

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

The rat carotid balloon injury is a well-established surgical model that has been used to study arterial remodeling and vascular cell proliferation. It is also a valuable model system to test, and to evaluate therapeutics and drugs that negate maladaptive remodeling in the vessel. The injury, or barotrauma, in the vessel lumen caused by an inflated balloon via an inserted catheter induces subsequent neointimal growth, often leading to hyperplasia or thickening of the vessel wall that narrows, or obstructs the lumen. The method described here is sufficiently sensitive, and the results can be obtained in relatively short time (2 weeks after the surgery). The efficacy of the drug or therapeutic against the induced-remodeling can be evaluated either by the post-mortem pathological and histomorphological analysis, or by ultrasound sonography in live animals. In addition, this model system has also been used to determine the therapeutic window or the time course of the administered drug. These studies can leadto the development of a better administrative strategy and a better therapeutic outcome. The procedure described here provides a tool for translational studies that bring drug and therapeutic candidates from bench research to clinical applications.

The rat carotid balloon injury model described below allows researchers to evaluate drugs or therapeutics that negate injury-induced arterial hyperplasia. Detailed pre-surgical preparation, surgical procedure, and post-surgical cares of the animal are described.

The rat carotid balloon injury is a well-established surgical model that has been used to study arterial remodeling and vascular cell proliferation. It is ...

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma is a disease of the central nervous system affecting retinal ganglion cells (RGCs). RGC axons making up the optic nerve carry visual input to the brain for visual perception. Damage to RGCs and their axons leads to vision loss and/or blindness. Although the specific cause of glaucoma is unknown, the primary risk factor for the disease is an elevated intraocular pressure. Glaucoma-inducing procedures in animal models are a valuable tool to researchers studying the mechanism of RGC death. Such information can lead to the development of effective neuroprotective treatments that could aid in the prevention of vision loss. The protocol in this paper describes a method of inducing glaucoma - like conditions in an in vivo rat model where 50 &#181;l of 2 M hypertonic saline is injected into the episcleral venous plexus. Blanching of the vessels indicates successful injection. This procedure causes loss of RGCs to simulate glaucoma. One month following injection, animals are sacrificed and eyes are removed. Next, the cornea, lens, and vitreous are removed to make an eyecup. The retina is then peeled from the back of the eye and pinned onto sylgard dishes using cactus needles. At this point, neurons in the retina can be stained for analysis. Results from this lab show that approximately 25% of RGCs are lost within one month of the procedure when compared to internal controls. This procedure allows for quantitative analysis of retinal ganglion cell death in an in vivo rat glaucoma model.

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma is characterized by damage to retinal ganglion cells. Inducing glaucoma in animal models can provide insight into the study of this disease. Here, we outline a procedure that induces loss of RGCs in an in vivo rat model and demonstrates the preparation of whole-mount retinas for analysis.

Glaucoma is a disease of the central nervous system affecting retinal ganglion cells (RGCs). RGC axons making up the optic nerve carry visual input to the ...

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption

Blood-brain barrier (BBB) coverage plays a central role in the homeostasis of the central nervous system (CNS). The BBB is dynamically maintained by astrocytes, pericytes and brain endothelial cells (BECs). Here, we detail methods to assess BBB coverage using single cultures of immortalized human BECs, single cultures of primary mouse BECs, and a humanized triple culture model (BECs, astrocytes and pericytes) of the BBB. To highlight the applicability of the assays to disease states, we describe the effect of oligomeric amyloid-&#946; (oA&#946;), which is an important contributor to Alzheimer&#39;s disease (AD) progression, on BBB coverage. Further, we utilize the epidermal growth factor (EGF) to illuminate the drug screening potential of the techniques. Our results show that single and triple cultured BECs form meshwork-like structures under basal conditions, and that oA&#946; disrupts this cell meshwork formation and degenerates the preformed mesh structures, but EGF blocks this disruption. Thus, the techniques described are important for dissecting fundamental and disease-relevant processes that modulate BBB coverage.

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption

Maintaining blood-brain barrier coverage is key for the homeostasis of the central nervous system. This protocol describes in vitro techniques to delineate the fundamental and pathological processes that modulate blood-brain barrier coverage.

Blood-brain barrier (BBB) coverage plays a central role in the homeostasis of the central nervous system (CNS). The BBB is dynamically maintained by ...

Improved Method for the Establishment of an In Vitro Blood-Brain Barrier Model Based on Porcine Brain Endothelial Cells

The aim of this protocol presents an optimized procedure for the purification and cultivation of pBECs and to establish in vitro blood-brain barrier (BBB) models based on pBECs in mono-culture (MC), MC with astrocyte-conditioned medium (ACM), and non-contact co-culture (NCC) with astrocytes of porcine or rat origin. pBECs were isolated and cultured from fragments of capillaries from the brain cortices of domestic pigs 5-6 months old. These fragments were purified by careful removal of meninges, isolation and homogenization of grey matter, filtration, enzymatic digestion, and centrifugation. To further eliminate contaminating cells, the capillary fragments were cultured with puromycin-containing medium. When 60-95% confluent, pBECs growing from the capillary fragments were passaged to permeable membrane filter inserts and established in the models. To increase barrier tightness and BBB characteristic phenotype of pBECs, the cells were treated with the following differentiation factors: membrane permeant 8-CPT-cAMP (here abbreviated cAMP), hydrocortisone, and a phosphodiesterase inhibitor, RO-20-1724 (RO). The procedure was carried out over a period of 9-11 days, and when establishing the NCC model, the astrocytes were cultured 2-8 weeks in advance. Adherence to the described procedures in the protocol has allowed the establishment of endothelial layers with highly restricted paracellular permeability, with the NCC model showing an average transendothelial electrical resistance (TEER) of 1249 &#177; 80 &#937; cm2, and paracellular permeability (Papp) for Lucifer Yellow of 0.90 10-6 &#177; 0.13 10-6 cm sec-1 (mean &#177; SEM, n=55). Further evaluation of this pBEC phenotype showed good expression of the tight junctional proteins claudin 5, ZO-1, occludin and adherens junction protein p120 catenin. The model presented can be used for a range of studies of the BBB in health and disease and, with the highly restrictive paracellular permeability, this model is suitable for studies of transport and intracellular trafficking.

Improved Method for the Establishment of an In Vitro Blood-Brain Barrier Model Based on Porcine Brain Endothelial Cells

The aim of the protocol is to present an optimized procedure for the establishment of an in vitro blood-brain barrier (BBB) model based on primary porcine brain endothelial cells (pBECs). The model shows high reproducibility, high tightness, and is suitable for studies of transport and intracellular trafficking in drug discovery.

The aim of this protocol presents an optimized procedure for the purification and cultivation of pBECs and to establish in vitro blood-brain barrier (BBB) ...

Endothelial Cell Transcytosis Assay as an In Vitro Model to Evaluate Inner Blood-Retinal Barrier Permeability

Dysfunction of the blood-retinal barrier (BRB) contributes to the pathophysiology of several vascular eye diseases, often resulting in retinal edema and subsequent vision loss. The inner blood-retinal barrier (iBRB) is mainly composed of retinal vascular endothelium with low permeability under physiological conditions. This feature of low permeability is tightly regulated and maintained by low rates of paracellular transport between adjacent retinal microvascular endothelial cells, as well as transcellular transport (transcytosis) through them. The assessment of retinal transcellular barrier permeability may provide fundamental insights into iBRB integrity in health and disease. In this study, we describe an endothelial cell (EC) transcytosis assay, as an in vitro model for evaluating iBRB permeability, using human retinal microvascular endothelial cells (HRMECs). This assay assesses the ability of HRMECs to transport transferrin and horseradish peroxidase (HRP) in receptor- and caveolae-mediated transcellular transport processes, respectively. Fully confluent HRMECs cultured on porous membrane were incubated with fluorescent-tagged transferrin (clathrin-dependent transcytosis) or HRP (caveolae-mediated transcytosis) to measure the levels of transferrin or HRP transferred to the bottom chamber, indicative of transcytosis levels across the EC monolayer. Wnt signaling, a known pathway regulating iBRB, was modulated to demonstrate the caveolae-mediated HRP-based transcytosis assay method. The EC transcytosis assay described here may provide a useful tool for investigating the molecular regulators of EC permeability and iBRB integrity in vascular pathologies and for screening drug delivery systems.

Endothelial Cell Transcytosis Assay as an In Vitro Model to Evaluate Inner Blood-Retinal Barrier Permeability

This protocol illustrates an in vitro endothelial cell transcytosis assay as a model to evaluate inner blood-retinal barrier permeability by measuring the ability of human retinal microvascular endothelial cells to transport horseradish peroxidase across cells in caveolae-mediated transcellular transport processes.

Dysfunction of the blood-retinal barrier (BRB) contributes to the pathophysiology of several vascular eye diseases, often resulting in retinal edema and ...